Modern possibilities of modified osteotherapy in bone metastases

A.V. Snegovoy, I.B. Kononenko

N.N. Blokhin National Medical Research Center of Oncology, Moscow

Bone metastasis is one of the most frequent manifestations of a common malignant process. Many tumours, especially breast, prostate, lung cancer and multiple myeloma are characterized by a high incidence of bone structures (up to 70–80%) and clinical complications. Intense pain syndrome, hypercalcemia, spinal cord compression, pathological fractures, the need for X-ray and surgical therapy (united by one common name — sceletal-related events (SRE)) can occur even with single metastases.

A multidisciplinary approach is used in treatment of patients with bone metastases. However, specific antitumor therapy and modified osteo-agents (MOA) are presented as the basis. Drugs capable of suppressing bone resorption include bisphosphonates, the most active of which is zoledronic acid. In addition to the inhibitory effect on bone resorption, zoledronic acid has antitumor properties that ensure the dr ug effectiveness for bone metastases. Another drug belonging to the MOA group is denosumab. It is a fully human monoclonal antibody with high affinity and specificity to the human RANK ligand (RANKL).

Keywords: bone metastases, modified osteo-agents (MOA), bisphosphonates, bone resorption markers, bone formation markers, zoledronic acid.

For citation: Snegovoy A.V., Kononenko I.B. Modern possibilities of modified osteotherapy in bone metastases. RMJ. 2019;6:16–22.